Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients

Transplantation

Volumn 79, Issue 6, 2005, Pages 716-721

  Haririan, Abdolreza ^a,c   Morawski, Katherina ^a   Sillix, Dale H ^a   El Amm, Jose M ^a   Garnick, James ^b   West, Miguel S ^a   Granger, Darla K ^a   Migdal, Stephen D ^a   Gruber, Scott A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

African American; Basiliximab; Induction; Kidney transplantation; Thymoglobulin

Indexed keywords

ANTIBODY; BASILIXIMAB; HLA ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C VIRUS; HLA MATCHING; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CREATINE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 16244423303     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000153506.07816.F0     Document Type: Article

References (33)

1. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Ann Intern Med 1998; 128: 817.
2. Monaco AP. A new look at polyclonal antilymphocyte antibodies in clinical transplantation. Graft 1999; 2(Suppl): 2.
3. Nashan B, Light S, Hardie IR, et al. Reduction of acute allograft rejection by daclizumab. Transplantation 1999; 67: 110.
4. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276.
5. Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343: 1545.
6. Gaston RS, Hudson SL, Deierhoi MH, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103.
7. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515.
8. Meier-Kriesche H, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366.
9. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with Thymoglobulin for renal transplant recipients. Transplantation 2002; 473.
10. Opelz G, Mickey MR, Terasaki PI. Influence of race on kidney transplant survival. Transplant Proc 1977; 9: 137.
11. Takemoto S, Terasaki PI. A comparison of kidney transplant survival in white and black recipients. Transplant Proc 1989; 21: 3865.
12. Koyama H, Cecka JM, Terasaki PI. Kidney transplants in black recipients. HLA matching and other factors affecting long-term graft survival. Transplantation 1994; 57: 1064.
13. Cosio FG, Dillon JJ, Falkenhain ME, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995; 47: 1136.
14. Cosio FG, Falkenhain ME, Pesavento TE, et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29: 419.
15. Benedetti E, Freels SA, Coady NT, et al. The impact of quadruple immunosuppression with OKT3 on kidney transplantation in black recipients. Am J Surg 1996; 172: 56.
16. Meier-Kriesche H, Kaza H, Palekar SS, et al. The effect of daclizumab in a high-risk renal transplant population. Clin Transplant 2000; 14: 509.
17. Sollinger H, Kaplan B, Pescovitz MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915.
18. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
19. Kode R, Fa K, Chowdhury S, et al. Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation. Clin Transplant 2003; 17: 369.
20. Kumar AM, Fa K, Vankawala R, et al. Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft survival. Transplant Proc 2001; 33: 3195.
21. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
22. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basilixamab versus anti-thymocyte globulins in renal transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
23. Mariat C, Afiani A, Alamartine E, et al. A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients. Transplant Proc 2001; 33: 3192.
24. Brennan DC, Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective, randomized, multicenter trial. Am J Transplant 2003; 3(Suppl 5): 438.
25. Scantlebury V, Fjertson D, Eliasziw M, et al. Influence of HLA and CREG matching in African-American primary cadaver kidney recipients: UNOS 1991-1995. Transplant Proc 1997; 29: 3733.
26. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
27. Meier-Kriesche H, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 70.
28. Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation 2002; 74: 675.
29. Meier-Kriesche H, Port FK, Ojo AL, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311.
30. Meier-Kriesche H, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. Transplantation 2002; 74: 1377.
31. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731.
32. Dupuis R, Van Beuge D, Conoley R, et al. Effectiveness of low dose valganciclovir in kidney and liver transplant recipients. Am J Transplant 2004; 4(Suppl 8): 337.
33. Gabardi S, Magee CC, Baroletti SA, et al. Rationale use of valganciclovir for the prevention of cytomegalovirus disease in renal transplant recipients. Am J Transplant 2004; 4(Suppl 8): 494.